Aslan Pharma Reports Positive Data for HER-2 Cancer Drug

Aslan Pharma of Singapore reported positive Phase II results from its lead candidate, varlitinib (ASLAN001) as a second-line treatment for metastatic HER-2 positive breast cancer. Varlitinib was administered in combination with capecitabine and compared to a Herceptin-capecitabine combination. The endpoint was tumor shrinkage at week 12. Aslan develops immunotherapies and targeted drugs for cancers that are prevalent in Asia. The company is expected to stage an IPO on the Taiwan exchange, probably sometime this year. More details.... Share this with colleagues: // //